TargeGen Eye Drop Well Tolerated in Human Study
Posted on: Wednesday, 28 February 2007, 12:01 CST
TargeGen has said preliminary data research from a phase I trial suggests that its eye drop was well tolerated in the treatment of macular degeneration and other debilitating diseases of the eye.
The eye drug TG100801, applied daily in eye drop form, is designed to suppress disease related edema, angiogenesis and inflammation simultaneously. Currently approved therapies for macular degeneration require repeated injection into the eye.
Preliminary results from this phase I study suggest that TG100801 is well tolerated in humans at the low and high doses tested when applied topically twice daily for 14 days.
Final study results are expected by the end of April 2007. TargeGen currently plans to initiate phase II clinical trials in wet age-related macular degeneration patients in mid-2007.
"The successful completion of this 'first in human' safety study with TG100801 represents a meaningful milestone for TargeGen and sets the stage for the near term initiation of human efficacy trials," stated Peter Ulrich, president, CEO and co-founder of TargeGen.
Source: Datamonitor
Related Articles
- Medical Study Establishes First-Ever Long-Term Benefits for Macular Degeneration Sufferers Using Macular Health Vitamin Supplement
- New Medical Study Establishes First-Ever Long-Term Benefits for Macular Degeneration Sufferers Using Macular Health Vitamin Supplement
- ThermoDox(R) Liver Cancer Study Phase I Results to Be Presented at ILCA Conference 2008
- Acucela Initiates Dosing in Phase I Macular Degeneration Trial
- TargeGen Initiates Multi-Center Phase II Clinical Trial Of TG100801, a Topically Applied Kinase Inhibitor In Macular Degeneration Patients
- Macular Degeneration Study is Funded
- GenVec Completes Enrollment in AdPEDF Clinical Study for Macular Degeneration
- Ista Eye Drop Looks Good in Phase II Study
- GenVec Macular Degeneration Study and Supporting Editorial Published in February Issue of Human Gene Therapy
- Columbia Laboratories Completes Lidocaine Vaginal Gel Pharmacokinetics Study; Phase II Study Planned
 |
 |
User Comments (0)
RSS Feeds